Сравнение
Icatibant vs. LL-37
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Исследования (прочее)
Исследования (прочее)
Номер CAS
138614-30-9
597562-32-8
Молекулярная масса
1304.52 g/mol
4493.33 g/mol
Период полувыведения
нет данных
нет данных
Последовательность
нет данных
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTESМеханизм действия
Icatibant
Icatibant competitively blocks the bradykinin B2 receptor. Because bradykinin mediates the vascular permeability, swelling and pain typical of hereditary angioedema, the blockade interrupts the acute attack.
LL-37
LL-37 is a cationic, amphipathic helical peptide and the only member of the cathelicidin family in humans. It is generated by proteolytic cleavage from the C-terminal portion of the precursor protein hCAP18 (CAP-18). Mechanistically it associates with and can permeabilize microbial membranes; in addition it modulates immune cells, influences cytokine release, exerts chemotactic activity, and can bind extracellular self-DNA. Preclinical models have described both anti-inflammatory and pro-inflammatory effects, depending on concentration and tissue context.
Доказательная база
Наивысшая доказательность
РКИ на людях
Исследование на людях
Исследования
1
4
из них на людях
1
1
Зафиксированные эффекты
1
4
Открытые противоречия
0
1
Задокументированные нежелательные явления
1
0
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between Icatibant and LL-37?
- Icatibant is classified as "Исследования (прочее)", while LL-37 is classified as "Исследования (прочее)". Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). LL-37: LL-37 is the only known human cathelicidin, a 37-amino-acid antimicrobial peptide generated by cleavage of the precursor protein hCAP18. In research it plays a central role in innate immune defence and wound healing, yet acts in a context-dependent manner as both anti- and pro-inflammatory and has been linked to autoimmune processes. LL-37 is not an approved drug; the evidence base is predominantly basic and preclinical. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Icatibant or LL-37?
- The highest available evidence level is "РКИ на людях" for Icatibant and "Исследование на людях" for LL-37. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Icatibant and LL-37 in Germany and the United States?
- Германия: Icatibant — Рецептурный, LL-37 — Только для исследований. США: Icatibant — Рецептурный, LL-37 — Только для исследований. These are factual summaries with source and review date on the individual pages.